NCT00347503View on ClinicalTrials.gov

Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients

PHASE4CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Cataract
Interventions
DRUG

ketorolac 0.4%, bromfenac 0.09%

Trial Locations (1)

18702

Bucci Laser Vision, Wilkes-Barre

Sponsors

Lead Sponsor

Innovative Medical
All Listed Sponsors
lead

Innovative Medical

INDUSTRY